Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants

Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations

“…Following more than 2,100 primary and 178 booster doses, there were no serious adverse events considered to be``related'' or``probably related'' to this vaccine. As observed before [14,15], reactogenicity increased with the booster dose. While the concomitant administration of Hib and DTaP vaccine used here precludes a true comparison of the frequency of general reactions, data from this study are similar to those observed when the same DTaP vaccine was given alone to German children during our previous trials [14,15,18].…”

“…As observed before [14,15], reactogenicity increased with the booster dose. While the concomitant administration of Hib and DTaP vaccine used here precludes a true comparison of the frequency of general reactions, data from this study are similar to those observed when the same DTaP vaccine was given alone to German children during our previous trials [14,15,18]. This is in contrast to reports where Hib-DTaP or Hibdiphtheria-tetanus-toxoid and whole cell pertussis vaccine (DTwP) vaccines caused a greater frequency of general reactions, primarily febrile, than after separate injections [5,11].…”

Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age

“…Despite higher GMCs for antibodies against all pertussis antigens after DTPa-IPV compared to dTpa-IPV, there was no difference between the groups in terms of vaccine response rates to each of the pertussis components. In addition, the antibody concentrations achieved in each of the groups were at least as high as those observed in infants who received primary vaccination with three doses of the same component DTPa vaccine (Infanrixe), and in whom efficacy against pertussis was subsequently demonstrated [19,20]. These results support the conclusion that booster vaccination with dTpa-IPV can provide protection against pertussis disease.…”

Randomized Trial on the Safety, Tolerability, and Immunogenicity of MenACWY-CRM, an Investigational Quadrivalent Meningococcal Glycoconjugate Vaccine, Administered Concomitantly with a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis Vaccine in Adolescents and Young Adults

“…While the limitations of cross-study comparison must be acknowledged, the pertussis antigen GMCs following concomitant administration of Tdap and MenACWY-CRM in the current study compared favorably with historical data observed in the infant studies demonstrating pertussis vaccine (DTaP) efficacy (17,18,20,21). The clinical relevance of this finding is not clear, since the correlates of protection for pertussis are not firmly established.…”